Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer

Long-Term Follow-Up of the Intergroup Exemestane Study

(2017) James P. Morden et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial

(2017) Marloes G M Derks et al.   LANCET ONCOLOGY

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

(2016) N. McGranahan et al.   SCIENCE

The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis

(2015) C. C. Engels et al.   BREAST CANCER RESEARCH AND TREATMENT

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

(2014) S. Loi et al.   ANNALS OF ONCOLOGY

Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients

(2014) H. R. Ali et al.   ANNALS OF ONCOLOGY

Effect of Aromatase Inhibition on Functional Gene Modules in Estrogen Receptor-Positive Breast Cancer and Their Relationship with Antiproliferative Response

(2014) Q. Gao et al.   CLINICAL CANCER RESEARCH

Lymphocytic infiltrate is associated with favorable biomarkers profile in HER2-overexpressing breast cancers and adverse biomarker profile in ER-positive breast cancers

(2013) Julia Y. S. Tsang et al.   BREAST CANCER RESEARCH AND TREATMENT

Tumor immune subtypes distinguish tumor subclasses with clinical implications in breast cancer patients

(2013) Esther M. de Kruijf et al.   BREAST CANCER RESEARCH AND TREATMENT

Molecular Profiling of Aromatase Inhibitor-Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance

(2013) A. K. Dunbier et al.   CLINICAL CANCER RESEARCH

Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients – an immunohistochemical study of cd8+ and foxp3+ using double immunostaining with correlation to the pathobiological response of the patients

(2013) Monica SM Chan et al.   INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS

Tumour-infiltrating FOXP3+ lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer

(2012) N R West et al.   BRITISH JOURNAL OF CANCER

Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer

(2011) Sahar M.A. Mahmoud et al.   JOURNAL OF CLINICAL ONCOLOGY

Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study

(2011) Judith M. Bliss et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial

(2011) Cornelis JH van de Velde et al.   LANCET

Immunomodulation of FOXP3+ Regulatory T Cells by the Aromatase Inhibitor Letrozole in Breast Cancer Patients

(2009) D. Generali et al.   CLINICAL CANCER RESEARCH

Immoderate inhibition of estrogen by anastrozole enhances the severity of experimental polyarthritis

(2009) Wang Jingxuan et al.   EXPERIMENTAL GERONTOLOGY